Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. is involved in the development of innovative therapeutics for the treatment of rare diseases with significant unmet medical needs. Self-described.

COM:CORBUSPHARMA

Corbus Pharmaceuticals Holdings, Inc.

Last Close

16.73

22/11 17:55

Market Cap

213.42M

Beta: -

Volume Today

80.06K

Avg: -

Financials Not Available